PTENP1 and breast carcinoma: The PTENP1 promoter has been shown to be hypermethylated in pancreatic adenocarcinoma, breast cancer, cervical cancer, ovarian cancer, and hepatocellular carcinoma cell lines [142], as well as in lymphoma [143], colorectal cancer [143], clear cell renal carcinoma cells [105,143], and NSCLC tissues [69].